SCHEMBL7134253

SCHEMBL7134253

O=S1(=O)CC(S(=O)(=O)c2ccccc2OCc2ccccc2)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
CA2 P00918 2/20 0.40
CA1 P00915 1/20 0.40
CA9 Q16790 1/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
HTR1A P08908 2/20 0.40
SLC6A3 Q01959 1/20 0.40
MGLL Q99685 1/20 0.37
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CDK4 P11802 1/20 0.36
CCNB1 P14635 1/20 0.36
CCND1 P24385 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
TNKS2 Q9H2K2 2/20 0.36
TDP1 Q9NUW8 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7133232 0.88 HTR1A (0.41) SLC6A4HTR1AMAPK1DRD2MEN1
Hydrochloric Acid SCHEMBL7159569 0.87 HTR1A (0.41) SLC6A4HTR1AMAPK1DRD2MEN1
SCHEMBL7134251 0.87 HTR2C (0.40) HTR2CHTR2BSLC6A2SLC6A4HTR1A
SCHEMBL7157696 0.82 SLC6A2 (0.37) SLC6A2SLC6A4PTK2BMEN1ALDH1A1
SCHEMBL7124572 0.81 HTR6 (0.41) HTR2CHTR2BSLC6A2SLC6A4ALDH1A1
SCHEMBL7126786 0.78 CA2 (0.45) CA2CA1CA9MGLLCCNB2
SCHEMBL7133231 0.76 HTR1A (0.41) SLC6A4HTR1AMAPK1DRD2ALDH1A1
SCHEMBL7126960 0.76 CA1 (0.42) CA2CA1CA9SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL7159572 0.76 HTR1A (0.40) SLC6A4HTR1AMAPK1DRD2MEN1
SCHEMBL7125024 0.74 HTR2A (0.33) HTR2CHTR2BCA2CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO HTR2C 4763/4885HTR2B 4830/4885CA2 3155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.